Table 4 Overall and EC-specific survival in patients according to gynecologic conditions.

From: Co-existence of leiomyomas, adenomyosis and endometriosis in women with endometrial cancer

EC Patient subgroupN Died (%)EC-specific SurvivalOverall Survival
aHR (95% CI)PaHR (95% CI)P
bIndividual conditions
Leiomyomas (n = 817)94 (11.5)0.67 (0.47–0.96)0.0270.68 (0.51–0.91)0.011
Adenomyosis (n = 572)56 (9.8)0.67 (0.44–1.04)0.0740.88 (0.63–1.21)0.431
Endometriosis (n = 179)23 (12.8)0.74 (0.39–1.40)0.3541.19 (0.75–1.88)0.458
Coexisting conditions
None (n = 352)71(20.2)1.00 1.00 
Leiomyomas only (n = 385)50 (13.0)0.58 (0.37–0.89)0.0120.57 (0.39–0.83)0.003
Adenomyosis only (n = 174)20 (11.5)0.52 (0.25–1.07)0.0760.77 (0.46–1.28)0.3
Endometriosis only (n = 37)4 (10.8)0.47 (0.14–1.54)0.210.56 (0.20–1.55)0.3
Leiomyomas & Adenomyosis (n = 309)27 (8.7)0.55 (0.31–0.98)0.0430.60 (0.38–0.95)0.03
Leiomyomas & Endometriosis (n = 53)10 (18.9)0.79 (0.31–2.00)0.6161.21 (0.62–2.38)0.6
Adenomyosis & Endometriosis (n = 19)2 (10.5)1.03 (0.14–7.54)0.9781.28 (0.31–5.27)0.7
All three conditions (n = 70)7 (10.0)0.25 (0.06–1.08)0.0640.74 (0.33–1.66)0.5
Prior/Concurrent Ovarian Cancer
No ovarian cancer (n = 1369)184 (13.4)1.00 1.00 
Prior/Concurrent ovarian cancer (n = 30)7 (23.3)0.55 (0.16–1.90)0.3431.18 (0.52–2.68)0.7
  1. EC, endometrial carcinoma; HR, Hazard Ratio; CI, confidence Interval; LVSI, lymphovascular space involvement.
  2. aEstimates are based on Cox modelling of factor variables using left-truncation; covariates includes age at EC diagnosis (continuous), FIGO stage I, II, III + IV (factor variables); histology endometrioid Grade 1, endometrioid Grade 2, endometrioid Grade 3, serous, clear cell, MMMT, other epithelial (factor variables) and LVSI no/unknown, yes.
  3. bAnalysis of EC patients with specified condition vs not, irrespective of presence of another condition.